| 07/22/2026 3:12 PM | ZenaTech (1997403) Filer | Form 6-K Report of foreign private issuer pursuant to Rule 13a-16 or 15d-16 under the Securities Exchange Act of 1934 | |
| 07/20/2026 8:58 PM | ZenaTech (1997403) Filer | Form 6-K Report of foreign private issuer pursuant to Rule 13a-16 or 15d-16 under the Securities Exchange Act of 1934 | |
| 06/24/2026 3:04 PM | ZenaTech (1997403) Filer | Form 6-K Report of foreign private issuer pursuant to Rule 13a-16 or 15d-16 under the Securities Exchange Act of 1934 | |
| 06/03/2026 1:20 PM | ZenaTech (1997403) Filer | Form 6-K Report of foreign private issuer pursuant to Rule 13a-16 or 15d-16 under the Securities Exchange Act of 1934 | |
| 06/03/2026 7:07 AM | ZenaTech (1997403) Filer | Form 6-K Report of foreign private issuer pursuant to Rule 13a-16 or 15d-16 under the Securities Exchange Act of 1934 | |
| 05/22/2026 4:08 PM | ZenaTech (1997403) Filer | Form 6-K Report of foreign private issuer pursuant to Rule 13a-16 or 15d-16 under the Securities Exchange Act of 1934 | |
| 05/18/2026 7:59 AM | ZenaTech (1997403) Filer | Form 424B5 | |
| 05/18/2026 7:00 AM | ZenaTech (1997403) Filer | Form 6-K Report of foreign private issuer pursuant to Rule 13a-16 or 15d-16 under the Securities Exchange Act of 1934 | |
| 05/15/2026 8:09 AM | ZenaTech (1997403) Filer | Form 6-K Report of foreign private issuer pursuant to Rule 13a-16 or 15d-16 under the Securities Exchange Act of 1934 | |
| 05/06/2026 9:47 AM | ZenaTech (1997403) Filer | Form 6-K Report of foreign private issuer pursuant to Rule 13a-16 or 15d-16 under the Securities Exchange Act of 1934 | |
| 05/04/2026 9:17 AM | ZenaTech (1997403) Filer | Form 20-F/A | |
Get the Latest News and Ratings for ZENA and Related Stocks Enter your email address below to receive the latest news and analysts' ratings for ZenaTech and its competitors with MarketBeat's FREE daily newsletter.
|
| 05/04/2026 9:18 AM | ZenaTech (1997403) Filer | Form 6-K Report of foreign private issuer pursuant to Rule 13a-16 or 15d-16 under the Securities Exchange Act of 1934 | |
| 04/29/2026 2:09 PM | ZenaTech (1997403) Filer | Form 20-F/A | |
| 04/29/2026 7:12 AM | ZenaTech (1997403) Filer | Form 20-F Registration statement / Annual report / Transition report | |
| 04/02/2026 2:33 PM | ZenaTech (1997403) Filer | Form 6-K Report of foreign private issuer pursuant to Rule 13a-16 or 15d-16 under the Securities Exchange Act of 1934 | |
| 04/02/2026 11:38 AM | Burns Thomas (2126013) Reporting ZenaTech (1997403) Issuer | Form 3 Initial statement of beneficial ownership of securities | |
| 04/02/2026 11:45 AM | Montgomery Linda (2126038) Reporting ZenaTech (1997403) Issuer | Form 3 Initial statement of beneficial ownership of securities | |
| 04/02/2026 11:28 AM | Passley Shaun (1671957) Filed by ZenaTech (1997403) Subject | Form SCHEDULE 13D/A | |
| 03/31/2026 3:58 PM | Asif Sajjad (2125375) Reporting ZenaTech (1997403) Issuer | Form 3 Initial statement of beneficial ownership of securities | |
| 03/30/2026 1:10 PM | Rattray Yvonne (2125163) Reporting ZenaTech (1997403) Issuer | Form 3 Initial statement of beneficial ownership of securities | |
| 03/26/2026 3:12 PM | Brown Neville (2124512) Reporting ZenaTech (1997403) Issuer | Form 3 Initial statement of beneficial ownership of securities | |
| 03/25/2026 4:19 PM | Passley Craig (2124007) Reporting ZenaTech (1997403) Issuer | Form 3 Initial statement of beneficial ownership of securities | |
| 03/24/2026 1:09 PM | Piekos Paul (2123538) Reporting ZenaTech (1997403) Issuer | Form 3 Initial statement of beneficial ownership of securities | |
| 03/18/2026 8:47 AM | Passley Shaun (1671957) Reporting ZenaTech (1997403) Issuer | Form 3 Initial statement of beneficial ownership of securities | |
| 03/11/2026 11:10 AM | Jennings Family Investments, Inc. (2109965) Filed by ZenaTech (1997403) Subject | Form SCHEDULE 13D | |
| 03/06/2026 2:27 PM | ZenaTech (1997403) Filer | Form 6-K Report of foreign private issuer pursuant to Rule 13a-16 or 15d-16 under the Securities Exchange Act of 1934 | |
| 02/27/2026 4:12 PM | ZenaTech (1997403) Filer | Form 20-F/A | |
| 02/23/2026 11:15 PM | ZenaTech (1997403) Filer | Form EFFECT | |
| 02/23/2026 1:31 PM | ZenaTech (1997403) Filer | Form F-3/A | |
| 02/23/2026 9:42 AM | Star Financial Corp (2068532) Filed by ZenaTech (1997403) Subject | Form SCHEDULE 13D/A | |
| 02/20/2026 9:16 AM | ZenaTech (1997403) Filer | Form 20-F/A | |
| 02/20/2026 8:52 AM | GG Mars Capital Inc (2069079) Filed by ZenaTech (1997403) Subject | Form SCHEDULE 13D/A | |
| 02/19/2026 3:56 PM | GG Mars Capital Inc (2069079) Filed by ZenaTech (1997403) Subject | Form SCHEDULE 13D/A | |
| 02/10/2026 4:25 PM | ZenaTech (1997403) Filer | Form F-3 Registration statement for securities of certain foreign private issuers | |
| 02/10/2026 9:10 AM | ZenaTech (1997403) Filer | Form 6-K Report of foreign private issuer pursuant to Rule 13a-16 or 15d-16 under the Securities Exchange Act of 1934 | |
| 01/27/2026 5:48 AM | ZenaTech (1997403) Filer | Form 6-K Report of foreign private issuer pursuant to Rule 13a-16 or 15d-16 under the Securities Exchange Act of 1934 | |
| 01/12/2026 8:46 AM | ZenaTech (1997403) Filer | Form 6-K Report of foreign private issuer pursuant to Rule 13a-16 or 15d-16 under the Securities Exchange Act of 1934 | |
| 12/16/2025 4:24 PM | ZenaTech (1997403) Filer | Form 6-K Report of foreign private issuer pursuant to Rule 13a-16 or 15d-16 under the Securities Exchange Act of 1934 | |
| 11/17/2025 9:36 AM | ZenaTech (1997403) Filer | Form 6-K Report of foreign private issuer pursuant to Rule 13a-16 or 15d-16 under the Securities Exchange Act of 1934 | |
| 11/10/2025 3:50 PM | ZenaTech (1997403) Filer | Form 6-K Report of foreign private issuer pursuant to Rule 13a-16 or 15d-16 under the Securities Exchange Act of 1934 | |
| 11/06/2025 2:12 PM | Star Financial Corp (2068532) Filed by ZenaTech (1997403) Subject | Form SCHEDULE 13D | |
FDA Clears This Under-$5 Biotech for Phase 2 Clinical Trial (Ad) A NASDAQ-listed biotech just cleared a major FDA milestone. Its lead therapy, Lucid-MS, has been cleared for Phase 2 trials in progressive multiple sclerosis.
Unlike existing treatments that suppress the immune system, Lucid-MS is designed to protect myelin. In pre-clinical models, it led to movement recovery including walking.
Independent research projects peak annual sales up to 5 billion dollars, yet shares still trade under 5 dollars. Learn why this FDA milestone could be a turning point for investors |
| 10/15/2025 3:06 PM | ZenaTech (1997403) Filer | Form 6-K Report of foreign private issuer pursuant to Rule 13a-16 or 15d-16 under the Securities Exchange Act of 1934 | |
| 09/24/2025 8:33 AM | GG Mars Capital Inc (2069079) Filed by ZenaTech (1997403) Subject | Form SCHEDULE 13D | |